Amazon.com Inc. (AMZN) could soon make retail pharmacy companies sick.
If the ecommerce giant enters into the retail pharmaceuticals industry, about 10% of pharmacy profits could be at risk, according to Morgan Stanley analysts.
These discussions suggest Amazon "could be taking on either pharmacy, drug distribution, or both," Morgan Stanley said. Amazon could enter the drug supply chain by opening a retail pharmacy, entering into contracts with generic drugmakers, working with branded manufacturers or building up a claims processing unit.
Should Amazon enter into the pharmacy market, there could be about a $1 decrease in generic co-pays that would eventually translate into a 10% to 11% headwind for the likes of CVS Health Corp. (CVS) and Walgreens Boots Alliance Inc. (WBA) in 2019.
According to the analysts, Amazon might simultaneously explore both opening a retail pharmacy and contracting generic drugmakers as the two have "low barriers to entry." Investors should watch for signals Amazon is filing for distribution licenses or opening some sort of retail pharmacy unit inside its Whole Foods locations.
The market for generic drugs would be a good one for Amazon -- Morgan Stanley says it represents a $79 billion gross profit opportunity across the supply chains. Retail pharmacy, too, could cushion the bottom line with a $52 billion profit pool.
Amazon stock traded lower 0.33% premarket Friday.
Now here's why Apple's former CEO is making a big bet on healthcare:
More of What's Trending on TheStreet:
- Warren Buffett Taught Me These 5 Amazing Investing Lessons to Use in 2018
- Don't Worry About Money So Much: 4 Ways to Fix Your Finances
- Riot Blockchain's Story Seems Like Something Out of the Dot-Com Bubble
- 3 Catastrophic Events Could Sink Bitcoin